Literature DB >> 3336027

N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.

B K Trivedi1, J A Bristol, R F Bruns, S J Haleen, R P Steffen.   

Abstract

Several N6-(arylalkyl)adenosines related to N6-benzyladenosine were synthesized, and their A1 and A2 adenosine receptor binding affinities were determined. The annulated derivative N6-(1-naphthylmethyl)adenosine resulted in a very potent A2 agonist (A1 Ki = 24 nM, A2 Ki = 9.1 nM), whereas N6-(9-anthracenylmethyl)adenosine was virtually inactive (A1 Ki = 9,000 nM, A2 Ki = 29,000 nM). Interestingly, the structurally similar N6-(9-fluorenylmethyl)adenosine was the most potent A2 agonist reported to date, with a Ki of 4.9 nM in A2 binding and 5.1 nM in A1 binding. The homologues N6-9-fluorenyladenosine and N6-[2-(9-fluorenyl)ethyl]adenosine showed little or no activity at either adenosine receptor. Effects of these agents on heart rate and coronary flow in the isolated rat heart paralleled their A1 and A2 binding affinities, respectively. These data suggest that for high affinity at the A2 receptor a planar hydrophobic function at a certain distance and angle from the N6 nitrogen is required.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3336027     DOI: 10.1021/jm00396a044

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor.

Authors:  A P IJzerman; P J Van Galen; K A Jacobson
Journal:  Drug Des Discov       Date:  1992

2.  9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.

Authors:  Jitesh R Shah; Philip D Mosier; Srinivas Peddi; Bryan L Roth; Richard B Westkaemper
Journal:  Bioorg Med Chem Lett       Date:  2009-12-23       Impact factor: 2.823

3.  Characterization of the adenosine receptors of the rat superior cervical ganglion.

Authors:  G P Connolly; T W Stone; F Brown
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.